BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7880610)

  • 1. The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2.
    Scharenberg JG; Stam AG; von Blomberg BM; Roest GJ; Palmer PA; Franks CR; Meijer CJ; Scheper RJ
    Eur J Cancer; 1994; 30A(12):1804-9. PubMed ID: 7880610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
    Hänninen EL; Knüver-Hopf J; Atzpodien J
    Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
    Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
    J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations.
    Soiffer RJ; Murray C; Ritz J; Phillips N; Jacobsohn D; Chartier S; Ambrosino DM
    Blood; 1995 Feb; 85(4):925-8. PubMed ID: 7849314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2).
    Allegretta M; Atkins MB; Dempsey RA; Bradley EC; Konrad MW; Childs A; Wolfe SN; Mier JW
    J Clin Immunol; 1986 Nov; 6(6):481-90. PubMed ID: 3491089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
    Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
    J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
    Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
    Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The detection and biological activity of human antibodies to IL-2 in normal donors.
    Tiberio L; Caruso A; Pozzi A; Rivoltini L; Morelli D; Monti E; Balsari A
    Scand J Immunol; 1993 Nov; 38(5):472-6. PubMed ID: 8235450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease.
    Atkins MB; Gould JA; Allegretta M; Li JJ; Dempsey RA; Rudders RA; Parkinson DR; Reichlin S; Mier JW
    J Clin Oncol; 1986 Sep; 4(9):1380-91. PubMed ID: 3489080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
    Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
    J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-interleukin-6 antibodies in normal human serum.
    Hansen MB; Svenson M; Diamant M; Bendtzen K
    Scand J Immunol; 1991 Jun; 33(6):777-81. PubMed ID: 2047765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
    Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.